<Ol> <Li> "Donor re-entry violations (e.g., HBsAg, anti-HIV - 1); </Li> <Li> (Certain) Violations relating to drug CGMP ...; </Li> <Li> Violative inspections of federal government agencies; </Li> <Li> Violative inspections of Team Biologics (Core Team) facilities for biologic products regulated by CBER; </Li> <Li> (Certain) Viral marker test run deficiencies ...; </Li> <Li> (Certain) Violations in areas where specific guidance has not been provided ...; </Li> <Li> Violations relating to HIV and HCV lookback; and </Li> <Li> Violative inspections of manufacturers of human cell, tissue, and cellular and tissue - based products (HCT / Ps)." </Li> </Ol> <Li> "Donor re-entry violations (e.g., HBsAg, anti-HIV - 1); </Li> <Li> (Certain) Violations relating to drug CGMP ...; </Li> <Li> Violative inspections of federal government agencies; </Li>

When does the fda issue a warning letter